3 Stocks Pushing The Health Care Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.0%) at 17,140 as of Wednesday, Sept. 17, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,738 issues advancing vs. 1,242 declining with 174 unchanged.

The Health Care sector currently sits up 0.6% versus the S&P 500, which is unchanged. Top gainers within the sector include Auxilium Pharmaceuticals ( AUXL), up 44.2%, Endo International ( ENDP), up 6.7%, Alnylam Pharmaceuticals ( ALNY), up 4.8%, Abbott Laboratories ( ABT), up 1.3% and Sanofi ( SNY), up 1.2%. On the negative front, top decliners within the sector include Baxter International ( BAX), down 2.8%, Gilead ( GILD), down 1.7%, DaVita HealthCare Partners ( DVA), down 1.3%, Medtronic ( MDT), down 0.9% and Covidien ( COV), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Salix Pharmaceuticals ( SLXP) is one of the companies pushing the Health Care sector higher today. As of noon trading, Salix Pharmaceuticals is up $4.13 (2.6%) to $160.00 on heavy volume. Thus far, 1.5 million shares of Salix Pharmaceuticals exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $158.32-$164.80 after having opened the day at $159.03 as compared to the previous trading day's close of $155.87.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. Salix Pharmaceuticals has a market cap of $9.5 billion and is part of the drugs industry. Shares are up 73.3% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Salix Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Salix Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Salix Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

Biotech Hits an Inflection Point

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

2 Small Biopharma Stocks on the Move

2 Small Biopharma Stocks on the Move